{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:08:27Z","timestamp":1750828107103},"reference-count":24,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.3892\/ol.2015.3852","type":"journal-article","created":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T07:48:13Z","timestamp":1446450493000},"page":"471-473","source":"Crossref","is-referenced-by-count":6,"title":["Fanconi anemia-D1 due to homozygosity for the BRCA2 gene Cypriot founder mutation: A case report"],"prefix":"10.3892","volume":"11","author":[{"given":"MARIA A.","family":"LOIZIDOU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANDREAS","family":"HADJISAVVAS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GEORGE A.","family":"TANTELES","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ELENA","family":"SPANOU-ARISTIDOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KYRIACOS","family":"KYRIACOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VIOLETTA","family":"CHRISTOPHIDOU-ANASTASIADOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,11,2]]},"reference":[{"key":"key20180108095254_b1-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMra0809889","article-title":"Susceptibility pathways in Fanconi's anemia and breast cancer","volume":"362","author":"D'Andrea","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180108095254_b2-ol-0-0-3852","article-title":"SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations), National Cancer Institute","author":"Howlader","year":"2012"},{"key":"key20180108095254_b3-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00043426-199709000-00004","article-title":"Infant cancer in the U.S.: Histology-specific incidence and trends, 1973 to 1992","volume":"19","author":"Gurney","year":"1997","journal-title":"J Pediatr Hematol Oncol"},{"key":"key20180108095254_b4-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1200\/JCO.2005.05.571","article-title":"Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group","volume":"23","author":"London","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108095254_b5-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0959-8049(97)00202-5","article-title":"The International Neuroblastoma Risk Groups (INRG): A preliminary report","volume":"33","author":"Castleberry","year":"1997","journal-title":"Eur J Cancer"},{"key":"key20180108095254_b6-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s12185-011-0777-z","article-title":"Fanconi anemia: A disorder defective in the DNA damage response","volume":"93","author":"Kitao","year":"2011","journal-title":"Int J Hematol"},{"key":"key20180108095254_b7-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1016\/j.yexcr.2006.06.014","article-title":"The Fanconi anemia\/BRCA pathway: A coordinator of cross-link repair","volume":"312","author":"Mirchandani","year":"2006","journal-title":"Exp Cell Res"},{"key":"key20180108095254_b8-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrc1321","article-title":"Tracing the network connecting BRCA and Fanconi anaemia proteins","volume":"4","author":"Venkitaraman","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"key20180108095254_b9-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1126\/science.1073834","article-title":"Biallelic inactivation of BRCA2 in Fanconi anemia","volume":"297","author":"Howlett","year":"2002","journal-title":"Science"},{"key":"key20180108095254_b10-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmg.2006.043257","article-title":"Clinical and molecular features associated with biallelic mutations in FANCD1\/BRCA2","volume":"44","author":"Alter","year":"2007","journal-title":"J Med Genet"},{"key":"key20180108095254_b11-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/pbc.23168","article-title":"The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1\/BRCA2 mutations","volume":"58","author":"Myers","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"key20180108095254_b12-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cancergencyto.2003.09.020","article-title":"Hereditary breast and ovarian cancer in Cyprus: Identification of a founder BRCA2 mutation","volume":"151","author":"Hadjisavvas","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"key20180108095254_b13-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/jnci\/djg072","article-title":"Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia","volume":"95","author":"Offit","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"key20180108095254_b14-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood-2003-06-1970","article-title":"Association of biallelic BRCA2\/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood","volume":"103","author":"Hirsch","year":"2004","journal-title":"Blood"},{"key":"key20180108095254_b15-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/blood-2003-09-3138","article-title":"Germline mutations in BRCA2: Shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia","volume":"103","author":"Wagner","year":"2004","journal-title":"Blood"},{"key":"key20180108095254_b16-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2407-7-152","article-title":"The BRCA1\/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers","volume":"7","author":"Friedenson","year":"2007","journal-title":"BMC Cancer"},{"key":"key20180108095254_b17-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1038\/sj.emboj.7601703","article-title":"BRCA2 is required for neurogenesis and suppression of medulloblastoma","volume":"26","author":"Frappart","year":"2007","journal-title":"EMBO J"},{"key":"key20180108095254_b18-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrg2159","article-title":"Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins","volume":"8","author":"Wang","year":"2007","journal-title":"Nat Rev Genet"},{"key":"key20180108095254_b19-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajmg.a.30853","article-title":"Should chromosome breakage studies be performed in patients with VACTERL association?","volume":"137","author":"Faivre","year":"2005","journal-title":"Am J Med Genet A"},{"key":"key20180108095254_b20-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1101\/gad.11.10.1226","article-title":"Targeted mutations of breast cancer susceptibility gene homologs in mice: Lethal phenotypes of Brca1, Brca2, Brca1\/Brca2, Brca1\/p53, and Brca2\/p53 nullizygous embryos","volume":"11","author":"Ludwig","year":"1997","journal-title":"Genes Dev"},{"key":"key20180108095254_b21-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1023\/A:1018792200700","article-title":"Developmental studies of Brca1 and Brca2 knock-out mice","volume":"3","author":"Hakem","year":"1998","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"key20180108095254_b22-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/humu.20625","article-title":"Genetic subtyping of Fanconi anemia by comprehensive mutation screening","volume":"29","author":"Ameziane","year":"2008","journal-title":"Hum Mutat"},{"key":"key20180108095254_b23-ol-0-0-3852","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2","volume":"14","author":"Roa","year":"1996","journal-title":"Nat Genet"},{"key":"key20180108095254_b24-ol-0-0-3852","first-page":"3663","article-title":"High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients","volume":"56","author":"Johannesdottir","year":"1996","journal-title":"Cancer Res"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2015.3852\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T11:37:16Z","timestamp":1515411436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2015.3852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,2]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,11,2]]},"published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.3892\/ol.2015.3852"],"URL":"https:\/\/doi.org\/10.3892\/ol.2015.3852","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,2]]}}}